Vanessa Caceres is a freelance medical writer and editor based in Florida. She has a BA in journalism and psychology and a Master's degree in teaching English as a second language/bilingual education. She writes regularly for ophthalmology and rheumatology physician publications, as well as other specialties.
A larger proportion of patients with gout had a therapeutic response at six months when treated with methotrexate and pegloticase than with pegloticase alone, according to results from the multi-center, open-label MIRROR (methotrexate to increase response rates in patients with uncontrolled gout receiving KRYSTEXXA) study, recently published in the Journal of Rheumatology.1 The MIRROR study… [Read More]
In the ACR Convergence 2021 session on Updates in OA, presenters discuss the debate over OA phenotypes vs. endotypes, as well as note that research conducted over the past 20 years yields a better understanding of the pathogenesis of OA.... [Read More]
The diverse topics, research & perspectives from this year’s ACR Convergence bring new insights for rheumatologists & all who care for their patients, according to speakers at the meeting’s Closing Session.... [Read More]
Targeted treatments for lupus still have a long way to go, but some studies are starting to pinpoint potential treatment pathways.... [Read More]
The new rheumatology-specific Merit-Based Incentive Payment System Value Pathway will focus on measures that most rheumatologists already track. The model should streamline reporting and better target quality improvements.... [Read More]
Keynote speaker Seema Yasmin, MD, brought her unique perspective to moving past the pandemic to improve provider mental health, address vaccine hesitancy and prepare for future health crises.... [Read More]
The MIPS Value Pathways will streamline federal reporting to better incentivize quality improvement. Start preparing for MVP with this session at ACR Convergence 2021.... [Read More]
As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis factor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medicine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib… [Read More]
At the recent Florida Society of Rheumatology meeting, ACR executive vice president Steven Echard, IOM, CAE, emphasized the role of collaborations with state organizations in the ACR’s plans to modernize and expand its activities and offerings. ... [Read More]
Presenters at the Access in Rheumatology meeting held in advance of the ACR’s State-of-the-Art Clinical Symposium took a deep dive into the access challenges faced by rheumatology patients and discussed possible solutions. Treatment At least until 2026, prescription drug spending will exceed the U.S. gross domestic product (GDP) and health spending, said rheumatologist Colin C…. [Read More]